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682CTLA-4 Blockade following Relapse of Malignancy after
Allogeneic Stem Cell Transplantation Is Associated with
T Cell Activation But Not with Increased Levels of
T Regulatory Cells
Jiehua Zhou,1 Asad Bashey,2 Ruikun Zhong,1 Sue Corringham,1 Karen Messer,1
Minya Pu,1 Wenxue Ma,1 Theresa Chut,1 Robert Soiffer,3 Rachel C. Mitrovich,3
Israel Lowy,4 Edward D. Ball1Cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) is a key negative regulator of T cell activation and
proliferation. Ipilimumab is a human monoclonal antibody that specifically blocks the binding of CTLA-4 to
its ligand. To test the hypothesis that blockade of CTLA-4 by ipilimumab could augment graft-versus-
malignancy (GVM) effects without a significant impact on graft-versus-host disease (GVHD), we conducted
a phase I clinical trial of ipilimumab infusion in patients with relapsed malignancy following allogeneic hemato-
poietic stem cell transplantation (allo-HSCT). Here, we report the analysis of peripheral blood T lymphocyte
reconstitution, Tregulatory cell (Treg) expression, and T cell activation markers after a single dose of ipilimu-
mab in 29 patients. Peripheral blood samples were collected from all patients before and after ipilimumab
infusion. Lymphocyte immunophenotyes, including levels of CD41CD25high cells and T cell activation
markers, were analyzed in all cases. Levels of CD41CD25highFoxp31 cells and intracellular CTLA-4 in
CD41T cells alsowere evaluated in the last 11 cases.We found lower baseline levels of CD41 andCD45RO1
T cells in patients comparedwith normal controls. More than 50%of the patients had abnormally low lympho-
cyte counts (CD4 or/and CD8 T cells), and some had no circulating B lymphocytes. The percentages of both
CD41CD25high and CD41CD25highFoxp31 T cells were significantly higher in patients before ipilimumab
infusion than in healthy donors. Twenty of 29 patients exhibited an elevated level of CD41CD25low activated
T cells at baseline, compared with only 3 of 26 healthy donors. Both CD41 and CD81 T lymphocyte counts
were significantly increased after ipilimumab infusion. Therewas no consistent change in absolute lymphocyte
count or in the number of T cells expressing the activation marker CD69. However, increases in
CD41CD25low T cells were seen in 20 of 29 patients and increases in CD41HLA-DR1 T cells were seen
in the last 10 patients in the first 60 days after ipilimumab infusion. Although the percentages of both
CD41CD25high and CD41CD25highFoxp31 T cells decreased significantly during the observation period,
the absolute cell counts did not change. Intracellular CTLA-4 expression in CD41CD25lo/- T cells increased
significantly after ipilimumab infusion. We conclude that CTLA-4 blockade by a single infusion of ipilimumab
increased CD41 and CD41HLA-DR1T lymphocyte counts and intracellular CTLA-4 expression at the high-
est dose level. Therewas no significant change in Treg cell numbers after ipilimumab infusion. These data dem-
onstrate that significant changes in T cell populations occur on exposure to a single dose of ipilimumab.
Further studies with multiple doses are needed to explore this phenomenon further and to correlate changes
in lymphocyte subpopulations with clinical events.
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Relapse of malignancy after allogeneic hematopoi-
etic stem cell transplantation (allo-HSCT) remains
a major obstacle to treatment success [1]. Conven-
tional treatment of relapse following allo-HSCT is
usually unsuccessful, and most patients eventually suc-
cumb to their malignancy. The exact mechanism be-
hind the failure of adoptive immunotherapy after
allo-HSCT is unclear but might include a lack of spe-
cific immune activation, lack of cancer-specific anti-
gens, poor antigen presentation to donor immune
cells, and a relative paucity of alloreactive lymphocytes
compared with the numbers of proliferating cancer
cells [1,2].
Regulatory T (Treg) cells are generated in the thy-
mus and function as immunosuppressive regulators.
They are best defined as a subset of CD41 T cells
with a phenotype of CD251 and Foxp31, and usually
account for \5% of the total CD41 T cells in the
peripheral blood [3,4]. Cytotoxic T lymphocyte
antigen 4 (CTLA-4) is expressed on effector T cells
following antigen-specific activation, where it func-
tions as a key negative regulatory factor. It is also con-
stitutively expressed on the Treg cell surface [5].
Identification of Treg cells has remained controversial
because of the lack of Treg-specific markers that sepa-
rate this lymphocyte subpopulation from activated
T effector cells [6]. Treg cells play a critical role inmain-
taining immune tolerance and regulating graft-versus-
host disease (GVHD) and graft-versus-malignancy
(GVM) effects. The mechanisms of immune suppres-
sion regulated by Treg cells have been found to require
cell contact between Treg and effector cells as well as
cytokines, such as interleukin (IL)-10 and transforming
growth factor b [7]. A recent report in a mouse model
found that Treg cells mediated suppression of
GVHD and GVM through different mechanisms [8].
GVHD suppression did not require granzyme B,
whereas previous studies had shown that granzyme B
was involved in suppression of antitumor responses.
Malignant cells can recruit Treg cells locally to sup-
press T cell function and create a favorable microenvi-
ronment for tumor cell growth [9-11]. Clinical studies
have shown an increased number ofTreg cells in tumor
sites, peripheral blood, and tumor-infiltrated lymph
nodes from both solid tumors and hematologic malig-
nancies [12]. This increased expression of Treg cells
has been associated with poor clinical outcomes [13].
The development of two CTLA-4 monoclonal anti-
bodies, ipilimumab and tremelimumab, has made
CTLA-4 an attractive target for cancer immunother-
apy. Clinical trials using ipilimumab or tremlimumab
as monotherapy or in combination with vaccines, cyto-
kines, or chemotheraputic reagents have been per-
formed in patients with metastatic melanoma, renal
cell carcinoma, non-Hodgkin lymphoma, and prostate,colon, and ovarian cancer [14-17]. Objective response
rates have been clearly related to antibody dose. The
antitumor response is often associated with immune-
related adverse events (IRAEs). CTLA-4 blockade–
mediated immune responses are associated with
tumor-specific cytotoxic T cell activation and expan-
sion. Clinical trials using CTLA-4 blockade found an
increase ofTh1 cytokines in patients’ plasma and an in-
crease in HLA-DR1 CD41 or CD81 T cells, whereas
the changes in CD41CD251 or CD41Foxp31 T
subsets, defined as Treg cells, were not consistent
[18-20]. The increase in activated T cells in the
circulation was highly correlated with antibody dose
in combination with granulocyte macrophage
colony-stimulating factor in a trial of patients with
metastatic prostate cancer [21]. In preclinical studies,
CTLA-4 blockade was found to modulate Treg cell
function without reducing Treg cell numbers, and
also to induce both CD4 and CD8 T cell activation
in murine models [22-24].
Treg cells may have several roles after allo-HSCT.
The importance of Treg cells in the prevention of
acute GVHD (aGVHD) after allo-HCT has been re-
ported [25,26]. The correlation of Treg cell numbers
and Foxp3 mRNA expression with chronic GVHD
(cGVHD) after allo-HSCT is not clear, however
[27,28]. The roles of Treg cells in immune
reconstitution, maintenance of the balance between
GVHD and GVM, and such treatments as donor
lymphocyte infusion and immunosuppressive drugs
are not well understood. Clinical studies have shown
that selective depletion of T lymphocytes, such as
CD251 T cells, in vitro can effectively reduce the
risk of aGVHD and cGVHD, but there are
disadvantages, including poor engraftment, increased
risk of relapse, and delayed immune reconstitution
leading to serious infectious complications. Attempts
have been made to separate the GVHD and GVM
effects; however, clinical trials in humans have shown
that the GVM effect and long-term survival are highly
associated with the presence of GVHD [29].
We have completed a clinical trial of CTLA-4
blockade in patients with relapse of malignancy after
allo-HSCT. This trial was based on the hypothesis
that augmenting the immune response to cancer cells
by blocking negative regulatory signals might improve
theGVM effect. This trial was facilitated by the advent
of a fully human monoclonal antibody capable of
blocking the interaction of CTLA-4 and Treg cells
and the interaction of ligands CD80/86 and antigen-
presenting cells. An escalating dose of ipilimumab
was given as a single i.v. infusion. The clinical results
of this study were reported previously [30]. Here, we
report the immunophenotypes of peripheral blood
T cells, including T cell reconstitution, activation,
and Treg expression, in 29 patients before and after
a single-dose infusion of ipilimumab.
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Patients
A total of 29 patients with relapsed malignancy af-
ter allo-HSCT were enrolled in this trial, including 14
withHodgkin disease, 6 withmultiplemyeloma, 2 with
acute myelogenous leukemia, 2 with chronic lympho-
cytic leukemia (CLL), 2with chronicmyelogenous leu-
kemia, 1with renal cell carcinoma, 1with breast cancer,
and 1 with non-Hodgkin lymphoma. The first 17 pa-
tients were enrolled in the dose-escalation phase of
the study, and the last 12 patients were in the phase II
portion of the study. The median time from transplan-
tation to enrollment in the studywas 21months (range,
4-79months). Characteristics of the patients were pub-
lished previously [30]. Before the trial, 3 patients had
extensive cGVHD, 4 patients had limited cGVHD,
and 3 patients had grade I/II aGVHD. Only 2 patients
remained in limited cGVHD at trial entry. In all pa-
tients, immunosuppressive drugs had been discontin-
ued for more than 6 weeks. Twenty-six patients had
progressive disease, 2 patients had stable disease, and
1 patient was in remission after 2 months of imatinib
therapy. Most patients had 100% donor chimerism in
both T cells and myeloid cells. Ipilimumab (Medarex,
Bloomsbury, NJ) was given as a single i.v. infusion
with a dose escalating from 0.1 mg/kg to 3 mg/kg.
No other immunomodulatory therapy was given dur-
ing the 60-day observation period. Peripheral blood
samples from all patients were obtained before ipilimu-
mab infusion (day 0) and on days 7, 14, 30, and 60 after
ipilimumab infusion. Blood samples were obtained on
days 1 and 3 from the later cohort of 14 patients.
Peripheral blood from 26 healthy individuals was
obtained from the San Diego Blood Bank and used
as normal controls. The peripheral blood lymphocytes
from 12 donors were separated and cultured with IL-2
(200 m/mL) for 3 days and used as controls for T cell
activation markers.
Lymphocyte Count
The absolute lymphocyte count (ALC) was calcu-
lated based on the percentage of lymphocytes in auto-
mated complete blood counts from peripheral blood.
Absolute cell count was calculated as ALC  percent-
age of expression of markers for T subset or B lympho-
cytes by flow cytometry analysis.
Antibodies
A panel of fluorescein isothiocyanate (FITC)-,
phycoerythrin (PE)-, or peridinin chlorophyll protein
complex (PerCP)-labeled antibodies, including CD3,
CD4, CD8, CD11a, CD16, CD19, CD25, CD38,
CD45RA, CD45RO, CD56, CD62L, C69, CD152
(CTLA-4), TCRab, TCRgd, and HLA-DR, and the
isotype controls, were purchased from BD Biosciences(San Jose, CA). T regulatory cell staining kits, includ-
ing CD4 FITC, CD25 PE, and Foxp3 PE-cy5 (clone
PCH102), and staining buffer sets were purchased
from eBioscience (San Diego, CA).
Flow Cytometry
Peripheral bloodmononuclear cells (PBMCs) were
obtained using a standard Ficoll-Hypaque density-
gradient centrifugation. Cells were stained with a panel
of antibodies and analyzed using FACScan and Cell-
quest software (BD Biosciences, San Jose, CA). For
analysis of intracellular Foxp3 expression, cells were
fixed after surface staining with CD4 FITC and
CD25 PE, washed with a permeabilization buffer,
and then stained with Foxp3 PE-cy5 or isotype
control. For analysis of CD41CD251 and
CD41CD251Foxp31 T cells, the CD41 cell region
was first gated using forward scatter versus FL1
(FITC) or FL3 (PerCP) in a dot plot. The
CD41CD25high and CD41CD25low regions were
then analyzed in a density plot. Treg cells were identi-
fied as a CD25 and Foxp3 dual-positive population.
The expressions of T cell activation markers, includ-
ing HLA-DR, CD69, and CD25, were analyzed in
either CD41 or CD81 T cell regions.
Statistical Analysis
For baseline values or changes from baseline, the
Mann-Whitney U test was used for between-group
comparisons, and Wilcoxon’s signed-rank test or the
paired t test was used for within-group comparisons.
For data collected over several time points, mixed-
effects models were used to test for a significant
within-group change over time, adjusted for such co-
variates as age at diagnosis and type of diagnosis. A ran-
dom intercept was used to account for correlation of
the data for each patient, and conditional studentized
residuals were plotted to check model fit. Pearson’s
correlation tests were used to test for a nonzero corre-
lation between two variables. Analyses were performed
using Prizm 5 (Graphpad Software, San Diego, CA)
and SAS version 9.2 (SAS Institute, Cary, NC). All
tests were two-sided at the 5% significance level.RESULTS
Flow Cytometry Analysis
Lymphocyte subset analysis
Eighteen patients had lymphocytopenia, defined as
an ALC\1500/mL in peripheral blood at baseline. Six
of these patients had both CD41 and CD81 T cell
counts\200/mL, and 10 patients had either a CD41
or CD81 count\200/mL. Five patients had no detect-
able CD191 B cells. Two patients with relapsed CLL
had an ALC.10,000/mL, and 70%-90% of these cells
Figure 1. (A) Lymphocyte phenotypes of patients at baseline and normal controls. The percentages of CD31, CD41, and CD45RO1 T cells are sig-
nificantly lower in patients than in the controls (P5.036,\.0001, and .032, respectively). (B) Absolute numbers of lymphocyte subsets in patients before
and after ipilimumab infusion at day 60. CD191 B cells were excluded in 2 cases of CLL to reduce the huge variation that this would cause. The cell counts
in all T cell subsets were increased significantly from day 0 to day 60 (Wilcoxon’s signed-rank test; P\.01 for the T subsets). Results are presented as
mean 6 SD.
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relapsed acute myelogenous leukemia had a small
percentage of circulating blasts. Figure 1A shows the
phenotypes of lymphocyte subsets from patients at
baseline and healthy individuals. Although the overall
pattern of lymphocyte subsets appeared to be similarFigure 2. Comparison of changes in CD41 and CD81 T cell counts in two
although most patients in the lower-dose group had lower CD41 T cell count
tistically significant (P5 .09). After ipilimumab infusion, the CD41CD31 T cell
day 60 (P 5 .049). (B) On day 0, the absolute cell count of CD81CD31 T cells
significant change in either group after ipilimumab infusion.in the patients and normal controls, the percentages
of CD31, CD41, and CD45RO1 T cells were signif-
icantly lower in the patients. The ratio of CD4 to CD8
T cells was close to 1:1 in the patients, significantly
lower that of 2:1 in the controls (P5 .01).We analyzed
the ALC counts of lymphocyte subsets at day 0 and daygroups of patients before and after ipilimumab infusion. (A) On day 0,
s than the patients in the higher-dose group, the difference was not sta-
count was significantly increased in the higher-dose group from day 0 to
did not differ in the two groups of patients (P 5 .52), and there was no
Figure 3. (A) Flow cytometry analysis of CD41CD25high Treg cells from two patients (designated A and B) shown in density plots of the CD41 T cell
region. In patient A, two regions in CD41 T cells were identified: CD25neg and a tail-like CD25high, without a clear-cut region of CD25low. This pattern
was identified in 9 of 29 patients as well as in 23 of 26 normal controls. In patient B, 3 regions in CD41 T cells were identified based on cell density:
CD25neg, CD25low, and a tail-like CD25high. MFI indicated the CD4 expression for each gated cell region, which was lower in CD41CD25high T cell
regions than in CD25low and CD25neg cell regions. This pattern was identified in 20 of 29 patients. (B) Expression of CD41CD25high T subset in
CD41 cells and absolute cell counts in 29 patients before and after ipilimumab infusion. There was a significant decrease in the percent expression
of the CD41CD25high T subset from baseline to day 60 (P 5 .04), but no change in the absolute cell count.
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onstrated significantly increased numbers at day 60.
Between day 0 and day 60, CD41 T cell count in-
creased in 19 patients (66%) and CD81 T cell count
increased in 23 patients (79%). In the 16 patients
with a baseline CD4 or/and CD8 cell count \200/
mL, 7 of 10 (70%) had an increased CD41T cell count
and 9 of 11 (82%) had an increased CD81T cell count.
There was no consistent change in the numbers of
CD191 B cells or CD561 CD161CD3neg NK cells
from day 0 to day 60 after ipilimumab infusion.
We compared the changes in ALC and counts of
CD41 and CD81 T cells in two groups of patients,
those who received \3 mg/kg of ipilimumab (n 5
14) and those who received 3 mg/kg of ipilimumab
(n 5 15). Figure 2 shows CD41 and CD81 T cell
counts from days 0, 7, 14, 30 and 60 in both groups.
We found a significant increase in CD41T cell count
from day 0 to day 60 in the patients who received thehigher dose. The median change was 95 cells/mL (in-
terquartile ranghe [IQR], 0-170) in the lower-dose
group and 260 cells/mL (IQR, 0-360) in the higher-
dose group (P 5 .049). There was no consistent
change in ALC and CD81 T cell count between the
two groups.
CD41CD25high Treg cells
We initially analyzed CD41CD25high T cells as
Treg cells in all 29 patients and 26 healthy donors by
the classical method [31]. Within the CD41 T cell re-
gion were 3 cell populations based on CD25 expres-
sion by density plot analysis: the CD25neg region, the
CD25low region, and a tail-like region with low mean
fluorescence intensity (MFI) for CD4 expression, de-
fined as the CD25high region (Figure 3A). At baseline,
the percentage of CD41CD25high T cells was signifi-
cantly higher in patients compared with healthy do-
nors (median, 7.2% [range, 1.5%-22%] vs 3.2%
Figure 4. Flow cytometry analysis of intracellular Foxp3 and CTLA-4 expression in CD41 T cells. The density plot analysis gated on CD41 T cells from
one patient on day 0 and on day 7 after ipilimumab infusion. The percentage of CD41CD25highFoxp31 cells was similar to the percentages of
CD41CD25high and CD41CD25highCTLA-41 T cells and did not change after treatment. Foxp3 also was expressed in CD41CD25lo/- cells, which
were slightly increased in this case after treatment. CTLA-4 expression in CD41CD25lo/- T cells increased 3-fold from baseline to day 7.
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a CD41 T cell count \200/mL; these patients had
a significantly higher baseline percentage of
CD41CD25high T cells compared with the other pa-
tients (median, 9.1% [range, 1.2%-22%] vs 6.7%
[1.8%-14%]; P 5 .04). The absolute cell count of
CD41CD25high T cells was 15/mL (range, 1-39/mL)
in patients with fewer CD41T cells and 28/mL (range,
5-116/mL) in those withmoreCD41Tcells. Figure 3B
shows the expression of CD41CD25highT cells in total
CD41 cells and the absolute cell counts from days 0, 7,
14, 30, and 60. In a mixed-effects model adjusted for
dose group, age, and diagnosis, in all 29 patients, the
percentage of CD41CD25highT cells decreased signif-
icantly over time after ipilimumab infusion (change
per month, 20.66%; 95% confidence interval (CI],
21.26% to 20.03%; P 5 .04), but the absolute
CD41CD25high cell count did not change significantly
(P 5 .10). The model for comparing counts used
percent change from baseline as the outcome.Detection of Foxp3 in CD41 T cells
When the antibody for Foxp3 became available for
flow cytometry studies, we analyzed intracellular levels
of Foxp3 and CTLA-4 in CD41T cells for the last 11
patients (who received a higher dose of ipilimumab)
and from 12 healthy donors. Figure 4 shows a repre-
sentative flow cytometry analysis of a patient before
and at day 7 after ipilimumab infusion. At baseline,
the percentage of CD41CD25highFoxp31Treg was
significantly higher in patients than in normalcontrols, accounting for a median of 3.0% (range,
0.4%-7.1%) of CD41 T cells in patients, compared
with 0.6% (range, 0.2%-3.9%) in controls (P 5 .004).
The absolute cell counts of CD41CD25highFoxp31
T cells (median, 11/mL; range 2-65/mL) and CD41
CD25high T cells (median, 15/mL; range, 6-67/mL)
were similar at baseline. Foxp31 cells were also found
in CD41CD25lo/- regions (Figure 4). CD41Foxp31
T cells accounted for amedian of 4.4%of CD41T cells
(range, 1.7%-10.7%) in patients, compared with 1.4%
(range, 0.2%-3.9%) in controls (P5 .002). Themedian
absolute cell count of CD41Foxp31T cells was 10/mL
(range, 5-96/mL) at baseline. Figure 5 shows the expres-
sion of CD41CD25highFoxp3 T cells in total CD41
cells and the absolute cell counts from days 0, 7, 14,
30, and 60.
From day 0 to day 60 after ipilimumab infusion,
the patients demonstrated a significant decrease in
the percentages of CD41CD25highFoxp31 Treg cells
(P 5 .02) and CD41Foxp31 T cells (P 5 .02), but
no significant change in both absolute cell counts
(P $.90). The model for comparing counts used per-
cent change from baseline as the outcome.
Detection of CTLA-4 in CD41 T cells
In the last 11 patients analyzed, intracellularCTLA-
4 expression was detected in both CD25high and
CD25lo/- cells, accounting for a median of 3.4% (range,
0.5%-8.6%) of CD41CD25high T cells and 5.8%
(range, 2.3%-12%) of CD41CD25lo/- T cells at base-
line. As shown in Figure 6, the expression of CD25,
Foxp3, and CTLA-4 in CD41 T cells was significantly
Figure 5. Expression of the CD41CD25highFoxp31 T subset in CD41 cells and the absolute cell count from the later 11 patients before and after
ipilimumab infusion. A significant decrease in the percentage expression in the CD41CD25highFoxp31 T subset is seen, (P 5 .02), but no change in ab-
solute cell count.
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absolute cell count ofCD41CD25highCTLA-41Tcells
was comparable to the CD41CD25highFoxp31 T cell
count at baseline (median, 17/mL; range, 1-65/mL).
TheCD41CD25lo/-CTLA-41Tcell countwas compa-
rable to the CD41Foxp31T cell count (median, 27/mL;
range, 5-99/mL).
The intracellular CTLA-4 expression in
CD41CD25lo/- T cells was significantly increased in
the 11 patients after ipilimumab infusion (change per
month, 6.3%; 95%CI, 2.7%-9.9%;P5 .001), as shown
in Figure 6. This increase was seen in almost all 11 pa-
tients at day 7 and was sustained to day 60 (data not
shown).Expression of T Cell activation markers
We analyzed CD69 expression on both CD41 and
CD81 T cells before and after ipilimumab infusion in
29 patients. At baseline, CD691 T cells accounted for
a median of 0.8% (range, 0-24%) of total CD41 TFigure 6. (A) Comparison of Foxp3 and CTLA-4 expression in CD41 T cell
Foxp3 and CTLA-4 in both CD25lo/- and CD25high T cells were significantly hi
counts of Foxp31 and CTLA-41 in CD41CD25high T cells did not change a
increased at day 60 (P 5 .001).cells in patients, compared with 0.3% (range, 0-5%)
in normal controls (n 5 12; P 5 .07). For CD81
T cells, the median was 2.1% (range, 0.3%-28%) of
CD691 T cells in patients and 2.0% (range, 0.5%-
4.3%) in controls (P5 .60). After ipilimumab infusion,
overall no significant change in CD69 expression was
seen in the 29 patients. However, the expression of
CD69 on either CD41 or CD81 T cells increased be-
tween 3- and 60-fold in 8 patients from day 7 to day 60.
We analyzed the expression of activation marker
CD25 on both CD41 and CD81 T cells. CD41
CD25low-activated T cells were detectable in 20 pa-
tients (n5 29) at baseline, but in only 3 of 26 controls.
Among these 20 patients, these cells accounted for
a median of 43% (range, 21%-64%) of the CD41
T cells at baseline. The percentage of CD81CD251
T cells was elevated to 10%-22% of CD81 T cells in
6 patients but in only 1 of 12 controls at baseline. After
ipilimumab infusion, no significant change in CD25
expression on CD81 T cells was noted. Although the
expression of CD41CD25low T cells remained stables in patients (n 511) and normal controls (n 5 12). The percentages of
gher in the patients than in the controls (P\.005). (B) The absolute cell
t day 60, but CD41CD25lo/-CTLA-41 T cell counts were significantly
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creased from day 0 to day 60, from a median of 134/mL
(range 23-482/mL) at baseline to a median of 237/mL
(range, 46-1197/mL) at day 60 (P 5 .01), for a daily
increase of 2.52 (95% CI, 1.26-3.78; P 5 .002).
WeanalyzedCD41HLA-DR1–activatedTcells in
the last 10 patients enrolled. At baseline, these ac-
counted for amedianof11%(range,3%-31%)ofCD41
Tcells in the patients, comparedwith 4.9% (range, 1%-
28%) in normal controls (n 5 16) (P 5 .02). After the
ipilimumab infusion, both the percentage expression
and the absolute cell count of CD41HLA-DR1T cells
were increased significantly in these 10 patients. The
absolute cell count increased from a median of 46/mL
(range, 6-134/mL) at baseline to 87/mL (range, 41-
683/mL) at day 60 (P5 .004).
Figure 7 shows the absolute cell counts of
CD41CD691, CD81CD691, CD41CD25low, and
CD41HLA-DR1 T cells in patients who received
an ipilimumab dose of 3 mg/kg before and after anti-
body infusion.Correlation with Clinical Findings
Clinical responsewas evaluatedmonthlybyphysical
examination, computed tomography scan, cytogenetic
analysis, polymerase chain reaction, and fluorescein in
situ hybridization analysis of bone marrow samples.
Three patients exhibited an objective response afterFigure 7. Analysis of activated T cells in patients receiving higher doses of
CD41CD25low T cells in the last 15 patients and of CD41HLA-DR1 cells i
CD41HLA-DR1 and CD41CD25low T cell counts increased significantly from
counts did not change significantly.ipilimumab infusion [30]. Comparing the responding
patients with the nonresponders reveals no significant
difference in the ALC and CD41CD25high T cell
counts. At 1 week after ipilimumab infusion, both
CD41 and CD81 T cell counts were increased in all 3
responding patients, and activated T cell counts in-
creased in 2 of them.
Clinical GVHD was evaluated monthly in all pa-
tients after ipilimumab infusion. No significant change
in GVHD status was seen in 2 patients with limited
cGVHD and in 8 patients with a previous history of
GVHD. Three patients with a history of aGVHD
had an ALC \1000/mL at baseline. Eight patients
had a high percentage of CD41CD25high T cells,
ranging from 5.4% to 15.7% of total CD41 T cells.
Nine patients received a donor lymphocyte infusion
after the ipilimumab infusion, and only one patient
developed grade I aGVHD.DISCUSSION
Allo-HSCT can cure a number of malignancies
through the GVM effect. This effect is even more im-
portant when reduced-intensity conditioning is used.
However, donor-derived alloreactive T cells can also
cause life-threateningGVHD. Activation of T cells re-
quires the recognition of specific antigens as well as
costimulatory molecules, such as CD80 and CD86,ipilimumab. The absolute counts of CD41CD691, CD81CD691, and
n the last 10 patients are shown before and after ipilimumab infusion.
baseline to day 60 (P 5.04 and .002, respectively), but CD691 T cell
690 Biol Blood Marrow Transplant 17:682-692, 2011J. Zhou et al.expressed on antigen-presenting cells. On activation,
CTLA-4 is up-regulated and expressed on the T cell
surface to provide negative feedback to activated T
cells. CTLA-4 is constitutionally expressed on Treg
cells. CTLA-4 blockade has been shown to induce an-
titumor effects in humans with melanoma and certain
other malignancies [14-17,32-34].
We studied Treg cells and T cell activation
markers in a unique group of patients who underwent
ipilimumab therapy for relapsed malignancy after
allo-HSCT. The patients received a single dose of
ipilimumab infusion in an attempt to augment GVM
and induce regression of malignancy. The median
time from allo-HSCT to ipilimumab infusion was 21
months. Immune reconstitution was incomplete in
more than 50% of the patients, based on low CD41
and CD81 T cell counts, inverted CD4:CD8 cell
ratios, and undetectable circulating CD191 B cells.
Various factors have a significant impact on immune
reconstitution after allo-HSCT, including previous
chemotherapy, underlying malignancy, conditioning
regimen, GVHD status, immunosuppressive therapy,
and the number of Treg cells and their functions.
Our clinical trial is the first attempt to study the effect
of CTLA-4 blockade on the expression of Treg cells
and T cell activation markers in this unique patient
population.
We report several interesting observations from
this trial. First, almost all patients had a significantly
higher percentage of Treg cells (both CD41CD25high
and CD41CD25highFoxp31 Tregs) compared with
the normal controls despite their lymphocytopenia
and low CD41 T cell counts. We found that the pa-
tients with a CD41T cell count\200/mL had a higher
proportion of CD41CD25high Treg cells compared
with those with a CD41 T cell count .200/mL.
Treg cells have been shown to suppress the prolifera-
tion, differentiation, and cytokine production of T
effector cells. The high percentage of Treg cells might
provide a potential explanation for the immune defi-
ciency and relapse of malignancy. The blockade of
CTLA-4 on Treg cells might contribute to the in-
creased number of T cells seen in most patients after
a single dose of ipilimumab. Clinical studies of patients
with myeloma who have undergone allo-HSCT have
shown that Treg cell reconstitution occurs earlier
and faster than conventional CD41 T cell reconstitu-
tion [35]. These CD41CD251Foxp31 Treg cells are
donor-derived memory-type T cells that expand pri-
marily in bone marrow. Treg cell reconstitution can
occur as early as day 30 posttransplantation in patients
who undergo CD25-depleted allo-HSCT. These
Treg cells are believed to derive from CD41CD25-
naı¨ve-type T cells by their intracellular Foxp3 expres-
sion [36].Whether there is a correlation between Treg
cell frequency and the status of cGVHD, as well as
long-term immune reconstitution, is a matter ofdebate.Without functional analysis, evaluating the po-
tency of the suppressive function of these Treg cells on
GVHD and GVM is difficult. A recent report from
a multicenter clinical trial of ipilimumab monotherapy
in patients with pretreated advanced melanoma (n 5
284) showed a dose-dependent efficacy. At a dose of
10 mg/kg, the patients had a significantly higher
response rate, although IRAEs were found in all dose
ranges, but a large increase in ALC was associated
with the highest antibody dose of 10 mg/kg [37].
Increases in both CD41 T cells and CD41Foxp31
Treg cells were reported in a clinical trial using
ipilimumab in patients with progressive metastatic
hormone-refractory prostate cancer [19]. The Treg
cell and T effector cell increases were found to be an-
tibody dose–dependent. It should be noted that Foxp3
can be induced in activated effector T cells [38].
Second, the finding of a high percentage of
CD41CD25low-activated T cells in 20 of 29 patients
certainly raises speculation that these donor-derived
T effector cells could be functionally activated to
mount a GVM attack against the original malignancy.
We have seen some evidence of a dose-dependent T
cell expansion and increased expression of T cell acti-
vation markers, such as HLA-DR, in 10 patients after
ipilimumab infusion. The patients who received the 3-
mg/kg dose of ipilimumab had significantly higher
CD41 T cell counts than those who received lower
doses, and significant increases in CD41HLA-DR1
activated T cell counts over time were seen in the
last 10 patients studied. This finding is similar to re-
sults from previous clinical studies of CTLA-4 block-
ade [39,40]. No significant changes in CD41CD25high
and CD41CD25highFoxp31 Treg cell counts were
seen. Despite the evidence of T cell expansion and
activation, we noted no clinically significant immune
reaction after ipilimumab infusion, even in the 3
patients who had an objective response.
These data lead us to believe it might be possible to
selectively activate the GVM effect without precipitat-
ing clinically significant GVHD.Our findings indicate
that ipilimumab at 3 mg/kg is safe in this patient pop-
ulation. This is a relatively low dose compared with the
doses used in phase III melanoma trials (10 mg/kg
given every 2 weeks). Because dose might be important
for optimal clinical effects, a higher dose and multiple
administrations may provide a more potent and long-
lasting GVM.
Previous studies have shown that T cells activated
by cytokines such as IL-2 and interferon-g have in-
creased levels of both surface and intracellular
CTLA-4 expression, where CTLA-4 plays an immu-
nosuppressive role [41]. CTLA-4 blockade may not
only affect Treg cell function, but also affect all acti-
vatedT cells, leading to antitumor activity and autoim-
mune adverse events [42,43]. In 11 patients studied
in our trial, intracellular CTLA-4 expression in
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ipilimumab infusion and persisted for 2 months,
whereas intracellular Foxp3 expression did not change
significantly. At the same time, we observed the ap-
pearance of newly activated T cells. We speculate
that the increased intracellular CTLA-4 levels might
be associated with T cell activation.
Treatment for relapsed malignancy after allo-
HSCT remains a major challenge. Methods to differ-
entiate GVHD and GVM will be an intense focus of
future research and clinical trials. Anti–CTLA-4 tar-
geted therapy is one option to selectively activate the
immune system, which may lead to augmented GVM
activity.We are planning a subsquent study ofmultiple
dosing of ipilimumab in this patient population when
the antibody becomes available for clinical trials.ACKNOWLEDGMENTS
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